In PrEP: Long-acting antivirals for HIV prevention

被引：1
|
作者：
Sharma, Amit [1 ]
机构：
[1] Ohio State Univ, Dept Microbial Infect & Immun, Dept Vet Biosci, Columbus, OH 43210 USA
来源：
CELL HOST & MICROBE | 2022年 / 30卷 / 02期
基金：
美国国家卫生研究院;
关键词：
PROPHYLAXIS; EFFICACY; MEN;
D O I：
10.1016/j.chom.2022.01.012
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Two recent publications (Vidal et al., 2021; Xue et al., 2022) report highly potent inhibitors as candidates for HIV pre-exposure prophylaxis (PrEP). They provide strong evidence that administration of long-acting capsid or fusion inhibitors as PrEP offers robust protection against simian-human immunodeficiency virus in the rhesus macaque model of HIV infection.
引用
收藏
页码：148 / 150
页数：3
相关论文
共 50 条
  • [31] Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities
    Meyers, Kathrine
    Golub, Sarit A.
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 290 - 295
  • [32] Long-Acting Cabotegravir for HIV Prevention Issues of Access, Cost, and Equity
    Sharfstein, Joshua M.
    Killelea, Amy
    Dangerfield, Derek
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (10): : 921 - 922
  • [33] Considerable interest in long-acting PrEP approaches among PrEP-users
    Almahfoud, Maher
    Matthews, Hanna
    Weimann, Lukas
    Scheiter, Robin Luca
    Huefner, Anja-Dorothee
    Weichel, Hanna-Marie
    Koch, Till
    Grenz, Marc
    Eckstein, Kai
    Schaefer, Guido
    Pestel, Julia
    Schmiedel, Stefan
    Degen, Olaf
    HIV MEDICINE, 2023, 24 : 71 - 72
  • [34] Preparing for long-acting PrEP delivery: building on lessons from oral PrEP
    Celum, Connie
    Grinsztejn, Beatriz
    Ngure, Kenneth
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [35] HIV PrEP Dose Rationale for Cabotegravir (GSK1265744) Long-acting Injectable Nanosuspension
    Spreen, Bill
    Rinehart, Alex
    Smith, Kimberly
    Margolis, David
    Ford, Susan
    Piscitelli, Steve
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 : A12 - A12
  • [36] A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP
    Yu, Yifan
    Bigos, Kristin L.
    Marzinke, Mark A.
    Landovitz, Raphael J.
    McCauley, Marybeth
    Ford, Susan
    Hendrix, Craig W.
    Bies, Robert R.
    Weld, Ethel D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (10) : 4623 - 4632
  • [37] HIGH INTEREST IN USING LONG-ACTING INJECTABLE PREP FOR HIV PREVENTION IN NATIONWIDE SAMPLE OF MALAYSIAN MEN WHO HAVE SEX WITH MEN
    Paudel, Kiran
    Gupta, Sana
    Wickersham, Jeffrey
    Azwa, Iskandar
    Khati, Antoine
    Akbar, Mohd
    Gautam, Kamal
    Shrestha, Roman
    ANNALS OF BEHAVIORAL MEDICINE, 2023, 57 : S181 - S181
  • [38] Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections
    Soriano, Vicente
    Barreiro, Pablo
    AIDS REVIEWS, 2020, 22 (02) : 124 - 127
  • [39] Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among US Men Who Have Sex with Men
    Greene, George J.
    Swann, Greg
    Fought, Angela J.
    Carballo-Dieguez, Alex
    Hope, Thomas J.
    Kiser, Patrick F.
    Mustanski, Brian
    D'Aquila, Richard T.
    AIDS AND BEHAVIOR, 2017, 21 (05) : 1336 - 1349
  • [40] Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa
    Ogunbajo, Adedotun
    Tsai, Alexander C.
    Kanki, Phyllis J.
    Mayer, Kenneth H.
    AIDS AND BEHAVIOR, 2022, 26 (07) : 2363 - 2375
12345